

## Investor Webinar on Rett Syndrome Phase I/II Clinical Trial Results

**Neurotech International Limited (ASX: NTI)** ("Neurotech" or "the Company"), a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders, today announces an investor webinar to discuss the Company's Phase I/II Rett Syndrome clinical trial results.

Executive Director Dr Thomas Duthy will present at **12pm AEST on Monday 6 May 2024**.

Shareholders, investors and interested parties are encouraged to register to attend the presentation at the following link: [https://us02web.zoom.us/webinar/register/WN\\_rDhlblzVSaahJ6IXTspJAw](https://us02web.zoom.us/webinar/register/WN_rDhlblzVSaahJ6IXTspJAw)

A recording will be available at the above link shortly after the conclusion of the live session, and the replay will also be available via the Company's website and social media channels. Questions can be submitted in advance to [matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au).

### Further Information

Dr Thomas Duthy  
Executive Director  
[td@neurotechinternational.com](mailto:td@neurotechinternational.com)  
+61 (0)402 493 727

### About Neurotech

**Neurotech International Limited (ASX:NTI)** is a clinical-stage biopharmaceutical development company focused predominately on paediatric neurological disorders with a broad-spectrum oral cannabinoid drug therapy called NTI164. Neurotech has completed a Phase II/III randomised, double-blind, placebo-controlled clinical trial in Autism Spectrum Disorder (ASD) with clinically meaningful and statistically significant benefits reported across a number of clinically-validated measures and excellent safety. In addition, Neurotech has completed and reported statistically significant and clinically meaningful Phase I/II trials in ASD and Paediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS) and Paediatric Acute-Onset Neuropsychiatric Syndrome (PANS), collectively PANDAS/PANS along with Rett Syndrome. Neurotech has received human ethics committee clearance for a Phase I/II clinical trial in spastic cerebral palsy.

For more information about Neurotech please visit <http://www.neurotechinternational.com>.